Ariad Pharnaceuticals Continues To Rally

Following a BMO Capital upgrade to Outperform and price target raised to $14, Ariad Pharmaceuticals

shares are 20% percent higher in Friday's trading at 9.24. Earlier in the session, the issue traded as high as 9.83. That is the highest level for ARIA since it cascaded from 17.14 on October 8, 2013.